Researchers in China have claimed to have achieved quantum supremacy, building a quantum computer capable of carrying out calculations trillions of times faster than today’s most powerful supercomputers…the computer, developed by a team of scientists at the University of Science and Technology of China in central Hefei, completed a calculation almost 100tn times quicker than existing supercomputers. The breakthrough comes a year after Google proclaimed itself the first to reach the milestone with its Sycamore machine. According to Lu Chaoyang, a professor in charge of the experiment at USTC, the Chinese computer achieved the breakthrough by manipulating particles of light.
Ho hum! Here is the FT article, more here, via John-March Russell here is extensive Scott Aaronson commentary, with many useful links. Here was my Thursday post. What is it — Sunday that is the day of rest?
Following an FBI investigation this summer, more than 1,000 researchers who had hidden their affiliation with the Chinese military fled the United States, the Justice Department said Wednesday.
Here is the full story.
Sight restored by turning back the epigenetic clock [in mice, to be clear]
Neurons progressively deteriorate with age and lose resilience to injury. It emerges that treatment with three transcription factors can re-endow neurons in the mature eye with youthful characteristics and the capacity to regenerate.
OK people, are you ready for Friday? C’mon, Eli, give ’em another dare!
Via Tom Jens.
Vaccine approval in the UK, protein folding advances, isn’t there a SpaceX launch today?, and now this:
Cultured meat, produced in bioreactors without the slaughter of an animal, has been approved for sale by a regulatory authority for the first time. The development has been hailed as a landmark moment across the meat industry.
The “chicken bites”, produced by the US company Eat Just, have passed a safety review by the Singapore Food Agency and the approval could open the door to a future when all meat is produced without the killing of livestock, the company said.
…The product would be significantly more expensive than conventional chicken until production was scaled up, but Eat Just said it would ultimately be cheaper.
…The growth medium for the Singapore production line includes foetal bovine serum, which is extracted from foetal blood, but this is largely removed before consumption. A plant-based serum would be used in the next production line, the company said, but was not available when the Singapore approval process began two years ago.
We document that since 1997, the rate of startup formation has precipitously declined for firms operated by U.S. PhD recipients in science and engineering. These are supposedly the source of some of our best new technological and business opportunities. We link this to an increasing burden of knowledge by documenting a long-term earnings decline by founders, especially less experienced founders, greater work complexity in R&D, and more administrative work. The results suggest that established firms are better positioned to cope with the increasing burden of knowledge, in particular through the design of knowledge hierarchies, explaining why new firm entry has declined for high-tech, high-opportunity startups.
Shawn Graham, a professor of digital humanities at Carleton University in Ottawa, uses a convolutional neural network called Inception 3.0, designed by Google, to search the internet for images related to the buying and selling of human bones. The United States and many other countries have laws requiring that human bones held in museum collections be returned to their descendants. But there are also bones being held by people who have skirted these laws. Dr. Graham said he had even seen online videos of people digging up graves to feed this market.
I’d shout it from the rooftops but my voice has become hoarse.
WBUR: In August, more than 100 New England colleges launched a massive experiment: What happens if you bring students back to petri dish campuses in the midst of a pandemic, but put huge energy into prevention culture and testing them once or twice a week?
The colleges partnered with the Broad Institute, a research giant that pivoted to mass coronavirus testing, in hopes the proposition could work well enough to salvage at least a partially on-campus fall.
As many students head home or settle back into their childhood bedrooms, the interim results of the experiment are now clear. The data show “that asymptomatic testing does work,” says Dr. Paula Johnson, president of Wellesley College and a leader of the group that put together the partnership. “And it works in terms of identifying cases quickly, paired with aggressive contact tracing. You identify a case, you identify the contacts. You pull them out of the system. And that really helps to prevent the spread.”
I’ve been a long-time reader of your blog, and I have enjoyed your analyses of how the pandemic could play out in the US.
I saw that you gave some space to Arnold Kling’s pessimistic take on the vaccines. I’m a volunteer in the J&J Phase 3 vaccine trial, and my experience of the trial design makes me more optimistic about the vaccines than even the headline numbers in the so-far announced trials would suggest. I think the trial set-ups particularly for J&J have some biases that would lead to understated effectiveness results:
First, these trials are effectively unblinded. The placebos are saline solution in J&J, AstraZeneca, Pfizer and Moderna. Per the Phase 2 results for J&J, >60% of participants had significant side effects, with flu-like symptoms the most common; I believe other vaccine trials had similarly intense side effects. When I got a shot, I was nearly bedridden for 24 hours; it felt as if I had the flu, and the effect was far more pronounced than for any other vaccine I’ve had. If I got the placebo, I need a psychotherapist. Though I plan to remain generally responsible and not take too many incremental risks, given I’m only mostly sure I got a vaccine that is still unproven, I’m sure my assumption that I’ve been vaccinated will influence my behavior, and the behavior of anyone else who has had significant side effects from their injection too.
Second, upcoming trials are likely going to suffer from a “too much COVID effect” on an absolute basis, and relative to prior trials in particular. J&J counts any infection more than 14 days after injection toward its efficacy calculation. If full immunity takes longer (and my understanding is that antibodies build after infections for 3+ weeks in many cases), then there will be people out there getting infected before the vaccine has taken full effect. That wasn’t particularly likely to happen in the summer when there were fewer cases overall. This is particularly going to affect 1-shot vaccines, as other trials have their effectiveness measured only after the second dose (but I could still imagine this dynamic having some impact, if full immunity builds gradually after the second dose).
Anyway, hope this is of some interest. I found it encouraging to conclude that study bias could understate, not overstate, the effectiveness of vaccines.
That is from my email, identity of the author is redacted.
Probably not, as I argue in my Bloomberg column. One problem is that advance market commitments work best when the output is well-defined, more or less homogeneous, and to be distributed according to very clear principles (one shot in the arm for everybody!). You can’t quite hand out green batteries or small nuclear reactors on the same basis. There is a case for subsidizing those, but not necessarily through advance purchase methods. Here is another part of the column:
Operation Warp Speed was also made easier by the internalization of vaccine research within companies or alliances of companies. The pre-purchase agreement limits risk, and within that framework the companies face strong competitive incentives to create a successful product. In the meantime, the work is removed from the public eye and debate, and at the end there is a definitive yes or no decision from the FDA. It is hardly simple, but it could be a lot more complicated.
In contrast, building a new energy infrastructure requires the cooperation of many companies and institutions, including local governments and regulators. One company can’t simply do everything (recall that the attempts of Alphabet to redesign part of Toronto as a new tech-based city met with local resistance and were ultimately put aside). The greater the number of institutions involved, the slower things get. Note that most of those institutions will not be getting pre-purchase funds from the federal government and they will face their usual bureaucratic and obstructionist incentives. When it comes to green energy policy, there are still too many veto points.
A striking feature of vaccine development is just how few social goals are involved. A vaccine should be safe, effective and easy to distribute. In broadly similar fashion, the highly successful Manhattan Project of the 1940s also had a small number of goals, namely a working and deliverable atomic bomb. When it comes to energy, there are already too many goals, and additional ones are often added: job creation, better design and community aesthetics, reductions in secondary pollution, regional economic benefits, and so on.
When I explain Fast Grants to people, and how it worked, it is always striking to me which part of the explanation they understand least. Everybody gets “we had a preexisting team in place, ready to handle accounting, recordkeeping, and payments.” Hardly anyone understands — really understands — “the program has two goals: supporting quality research projects that will feed into stopping Covid, and speed.” On one hand, it sounds self-evident to them, but on the other hand I don’t think they realize how much the intellectual infrastructure of the project really is defined by those goals and no others. Nothing about meeting payroll, or pursuing other meritorious social goals, or getting grant or donor renewal, or raising the stature of the program in the biomedical community, or…? What you choose not to pursue is one of the most radical steps you can take, and often it is so radical that other people don’t even grasp or notice it. They just don’t see you “not doing something.” That can be a good way to innovate!
He is a well-known chemist (and more) at UC San Diego. We started with classic Star Trek and then moved into textiles, chemistry, music vs. sound, nanobots against Covid, how to interview, traveling during a pandemic, art collecting and voodoo flags, the importance of materials science, and much more. Mostly he interviewed me, though it went a bit both ways.
Almost 100% fresh material and topics, and here is the Spotify link.
No, according to Barry Eichengreen, Cevat Giray Aksoy, and Orkun Saka:
It is sometimes said that an effect of the COVID-19 pandemic will be heightened appreciation of the importance of scientific research and expertise. We test this hypothesis by examining how exposure to previous epidemics affected trust in science and scientists. Building on the “impressionable years hypothesis” that attitudes are durably formed during the ages 18 to 25, we focus on individuals exposed to epidemics in their country of residence at this particular stage of the life course. Combining data from a 2018 Wellcome Trust survey of more than 75,000 individuals in 138 countries with data on global epidemics since 1970, we show that such exposure has no impact on views of science as an endeavor but that it significantly reduces trust in scientists and in the benefits of their work. We also illustrate that the decline in trust is driven by the individuals with little previous training in science subjects. Finally, our evidence suggests that epidemic-induced distrust translates into lower compliance with health-related policies in the form of negative views towards vaccines and lower rates of child vaccination.
Here is the link to the NBER working paper.
A very important result from Ahmed, Hoddinott, Abedin and Hossain in The American Journal of Agricultural Economics. Bt eggplant offers a 51% increase in yield, a 37.5% decrease in pesticide use, increased farmer profits and decreased farmer sickness. Wow!
We implemented a cluster randomized controlled trial to assess the impact of genetically modified eggplant (Bt brinjal) in Bangladesh. Our two primary outcomes were changes in yield and in pesticide costs. Cultivation of Bt brinjal raises yields by 3,564 kg/ha. This statistically significant impact is equivalent to a 51% increase relative to the control group. There is a statistically significant fall in pesticide costs, 7,175 Taka per hectare (85 USD per ha), a 37.5% reduction. Yield increases arise because Bt farmers harvest more eggplant and because fewer fruits are discarded because they are damaged. Bt brinjal farmers sell more eggplant and receive a higher price for the output they sell while incurring lower input costs, resulting in a 128% increase in net revenues. Bt brinjal farmers used smaller quantities of pesticides and sprayed less frequently. Bt brinjal reduced the toxicity of pesticides as much as 76%. Farmers growing Bt brinjal and who had pre‐existing chronic conditions consistent with pesticide poisoning were 11.5% points less likely to report a symptom of pesticide poisoning and were less likely to incur cash medical expenses to treat these symptoms. Our results are robust to changes in model specification and adjustment for multiple hypothesis testing. We did not find evidence of heterogeneous effects by farmer age, schooling, or land cultivated. Bt brinjal is a publicly developed genetically modified organism that conveys significant productivity and income benefits while reducing the use of pesticides damaging to human and ecological health.
Hat tip: Marc Bellemare.
Erasmus Darwin plunged into popular scientific poetry. Cantering along in the style — if not with the elegance — of Alexander Pope, he never aspired to greatness. His verses, however, were remarkable for their vivid pictures of evolution interlaced with stirring accounts of the advancement of science, technology, and human culture during the late eighteenth century, the very epitome of optimistic entrepreneurial thought applied to the natural world in the bright glow of the prerevolutionary era.
It is hard to recapture the full extent of the fame these writings, virtually forgotten today, brought him. Yet for many readers of the 1790s, Darwin was the poet for the age of liberty and social advance: an advocate of industrialisation and cultural improvement; an avid admirer of the power of steam; a discipline of the French philosophes, revealing his Jacobin-like fervour for change and transformation at every turn, and deliberately provocative in taking as his publisher the radical Joseph Johnson, the Londoner who printed William Godwin and friends; at all times a poet of progress, with such an obvious sense of humor that his zest for life could not fail to amuse.
I don’t think so, as I argue in my latest Bloomberg column, here is one bit:
If you are wondering whether China or the U.S. with its allies is more likely to make a big breakthrough, in, say, quantum computing, ask yourself a simple question: Which network will better attract talented immigrants? The more that talent and innovation are found around the world, the more that helps the U.S.
Perhaps most important, the European Union has evolved from seeing China primarily as a customer to seeing China primarily as a rival. Even Germany, a longstanding advocate for closer ties with China, has become more skeptical. Furthermore, most European nations have ended up agreeing with the U.S. that Chinese telecom giant Huawei be kept out of the critical parts of their communications infrastructure.
It is also worth noting that GPT-3 came out of the Anglosphere, not China, even though we have been hearing for years that China may be ahead in AI.